Management of Preexisting Diabetes in Pregnancy: A Review.

Anastasia-Stefania Alexopoulos, Rachel Blair, Anne L Peters
Author Information
  1. Anastasia-Stefania Alexopoulos: Duke University Medical Center, Durham, North Carolina.
  2. Rachel Blair: Brigham and Women's Hospital, Boston, Massachusetts.
  3. Anne L Peters: Keck School of Medicine of the University of Southern California, Los Angeles.

Abstract

Importance: The presence of preexisting type 1 or type 2 diabetes in pregnancy increases the risk of adverse maternal and neonatal outcomes, such as preeclampsia, cesarean delivery, preterm delivery, macrosomia, and congenital defects. Approximately 0.9% of the 4 million births in the United States annually are complicated by preexisting diabetes.
Observations: Women with diabetes have increased risk for adverse maternal and neonatal outcomes, and similar risks are present with type 1 and type 2 diabetes. Both forms of diabetes require similar intensity of diabetes care. Preconception planning is very important to avoid unintended pregnancies and to minimize risk of congenital defects. Hemoglobin A1c goals are less than 6.5% at conception and less than 6.0% during pregnancy. It is also critical to screen for and manage comorbid illnesses, such as retinopathy and nephropathy. Medications known to be unsafe in pregnancy, such as angiotensin-converting enzyme inhibitors and statins, should be discontinued. Women with obesity should be screened for obstructive sleep apnea, which is often undiagnosed and can result in poor outcomes. Blood pressure goals must be considered carefully because lower treatment thresholds may be required for women with nephropathy. During pregnancy, continuous glucose monitoring can improve glycemic control and neonatal outcomes in women with type 1 diabetes. Insulin is first-line therapy for all women with preexisting diabetes; injections and insulin pump therapy are both effective approaches. Rates of severe hypoglycemia are increased during pregnancy; therefore, glucagon should be available to the patient and close contacts should be trained in its use. Low-dose aspirin is recommended soon after 12 weeks' gestation to minimize the risk of preeclampsia. The importance of discussing long-acting reversible contraception before and after pregnancy, to allow for appropriate preconception planning, cannot be overstated.
Conclusions and Relevance: Preexisting diabetes in pregnancy is complex and is associated with significant maternal and neonatal risk. Optimization of glycemic control, medication regimens, and careful attention to comorbid conditions can help mitigate these risks and ensure quality diabetes care before, during, and after pregnancy.

References

  1. Diabetes. 2000 Dec;49(12):2208-11 [PMID: 11118027]
  2. J Matern Fetal Neonatal Med. 2002 Dec;12(6):408-12 [PMID: 12683652]
  3. Postgrad Med J. 2003 Aug;79(934):454-7 [PMID: 12954957]
  4. Hum Exp Toxicol. 2003 Dec;22(12):623-8 [PMID: 14992323]
  5. Kidney Int. 2004 Jun;65(6):1991-2002 [PMID: 15149313]
  6. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005542 [PMID: 17636806]
  7. Diabetes Care. 2008 Jan;31(1):9-14 [PMID: 17909091]
  8. Am J Obstet Gynecol. 2008 Sep;199(3):237.e1-9 [PMID: 18674752]
  9. BMJ. 2008 Sep 25;337:a1680 [PMID: 18818254]
  10. J Clin Endocrinol Metab. 2009 Nov;94(11):4284-91 [PMID: 19808847]
  11. Diabetes Care. 2011 Feb;34(2):406-11 [PMID: 21216859]
  12. Diabetes Care. 2011 Jul;34(7):1481-6 [PMID: 21593294]
  13. Diabetes Care. 2011 Aug;34(8):1683-8 [PMID: 21636798]
  14. Obstet Gynecol. 2011 Jul;118(1):197-8 [PMID: 21691184]
  15. Diabetes Care. 2011 Oct;34(10):2279-84 [PMID: 21949222]
  16. Diabetes Care. 2011 Dec;34(12):2527-9 [PMID: 22011408]
  17. Diabetes Metab. 2013 Apr;39(2):139-47 [PMID: 23219072]
  18. Diabetes Care. 2013 Jul;36(7):1877-83 [PMID: 23349548]
  19. Diabetes Obes Metab. 2013 Oct;15(10):888-900 [PMID: 23489521]
  20. Cochrane Database Syst Rev. 2013 Jul 31;(7):CD001449 [PMID: 23900968]
  21. Adv Chronic Kidney Dis. 2013 May;20(3):209-14 [PMID: 23928384]
  22. Obstet Gynecol. 2014 Jan;123(1):167-78 [PMID: 24463678]
  23. Contraception. 2015 Jan;91(1):67-70 [PMID: 25193535]
  24. CMAJ Open. 2014 Jul 22;2(3):E162-75 [PMID: 25295236]
  25. N Engl J Med. 2015 Jan 29;372(5):407-17 [PMID: 25629739]
  26. Diabetes Care. 2015 May;38(5):821-6 [PMID: 25710920]
  27. JAMA. 2015 Apr 14;313(14):1425-34 [PMID: 25871668]
  28. J Diabetes Res. 2015;2015:325851 [PMID: 25874236]
  29. Diabetologia. 2015 Jul;58(7):1454-63 [PMID: 25924986]
  30. Diabetes Care. 2015 Jul;38(7):1238-44 [PMID: 26070588]
  31. Clin J Am Soc Nephrol. 2015 Nov 6;10(11):1964-78 [PMID: 26487769]
  32. J Fam Plann Reprod Health Care. 2016 Apr;42(2):93-8 [PMID: 26645197]
  33. Diabetes Technol Ther. 2016 Feb;18 Suppl 2:S243-7 [PMID: 26784129]
  34. N Engl J Med. 2016 Mar 3;374(9):843-52 [PMID: 26962904]
  35. Curr Diabetes Rev. 2017;13(3):315-321 [PMID: 27097605]
  36. Diabetes Care. 2016 Aug;39(8):1356-63 [PMID: 27271191]
  37. BMC Pregnancy Childbirth. 2016 Jul 19;16(1):173 [PMID: 27435163]
  38. N Engl J Med. 2016 Aug 18;375(7):644-54 [PMID: 27532830]
  39. Obstet Med. 2011 Dec;4(4):133-9 [PMID: 27579111]
  40. Hypertension. 2016 Nov;68(5):1153-1159 [PMID: 27620393]
  41. Am J Obstet Gynecol. 2017 Feb;216(2):110-120.e6 [PMID: 27640943]
  42. J Clin Lipidol. 2016 Sep-Oct;10(5):1081-90 [PMID: 27678424]
  43. Obstet Gynecol. 2016 Nov;128(5):1095-1104 [PMID: 27741196]
  44. BMJ Open. 2016 Dec 23;6(12):e013509 [PMID: 28011814]
  45. Thyroid. 2017 Mar;27(3):315-389 [PMID: 28056690]
  46. JAMA. 2017 Jan 10;317(2):183-189 [PMID: 28097362]
  47. J Matern Fetal Neonatal Med. 2018 Jul;31(14):1933-1939 [PMID: 28574296]
  48. Metabolism. 2017 Jul;72:47-56 [PMID: 28641783]
  49. Curr Diab Rep. 2017 Aug;17(8):58 [PMID: 28660565]
  50. N Engl J Med. 2017 Jul 20;377(3):301 [PMID: 28723318]
  51. Expert Opin Drug Metab Toxicol. 2017 Oct;13(10):1029-1038 [PMID: 28847172]
  52. Lancet. 2017 Nov 25;390(10110):2347-2359 [PMID: 28923465]
  53. Oncotarget. 2017 May 11;8(37):61048-61056 [PMID: 28977845]
  54. Sleep Med. 2017 Oct;38:50-57 [PMID: 29031756]
  55. Diabetes Care. 2017 Dec;40(12):1746-1755 [PMID: 29038315]
  56. Am J Obstet Gynecol. 2018 Mar;218(3):287-293.e1 [PMID: 29138036]
  57. Diabetes Metab. 2018 Feb;44(1):4-14 [PMID: 29217386]
  58. PLoS One. 2018 Jan 12;13(1):e0190676 [PMID: 29329330]
  59. Congenit Heart Dis. 2018 Mar;13(2):271-281 [PMID: 29363266]
  60. Diabetes Care. 2018 Apr;41(4):789-796 [PMID: 29444895]
  61. J Clin Sleep Med. 2018 Mar 15;14(3):327-336 [PMID: 29458699]
  62. J Clin Endocrinol Metab. 2018 Apr 1;103(4):1612-1621 [PMID: 29490031]
  63. Diabetes Care. 2018 Jul;41(7):1391-1399 [PMID: 29535135]
  64. J Clin Endocrinol Metab. 2018 Jun 1;103(6):2302-2308 [PMID: 29584894]
  65. Diabetes Obes Metab. 2018 Aug;20(8):1894-1902 [PMID: 29603547]
  66. Hypertension. 2018 Jun;71(6):1170-1177 [PMID: 29686009]
  67. JAMA. 2018 May 1;319(17):1773-1780 [PMID: 29715355]
  68. Can J Cardiol. 2018 May;34(5):526-531 [PMID: 29731014]
  69. Am J Obstet Gynecol. 2018 Oct;219(4):367.e1-367.e7 [PMID: 29959933]
  70. JAMA. 2018 Jul 24;320(4):397-398 [PMID: 29984374]
  71. Diabetologia. 2018 Nov;61(11):2319-2332 [PMID: 30008062]
  72. Am J Obstet Gynecol. 2018 Oct;219(4):405.e1-405.e7 [PMID: 30012335]
  73. Diabetes Care. 2018 Oct;41(10):2155-2161 [PMID: 30089663]
  74. Obstet Gynecol. 2018 Oct;132(4):875-881 [PMID: 30204701]
  75. Sleep Breath. 2019 Jun;23(2):399-412 [PMID: 30255484]
  76. Diabetes Care. 2018 Dec;41(12):2471-2479 [PMID: 30327362]
  77. Diabetes Care. 2018 Dec;41(12):2502-2508 [PMID: 30373735]
  78. MMWR Morb Mortal Wkly Rep. 2018 Nov 02;67(43):1201-1207 [PMID: 30383743]
  79. Diabetologia. 2019 Feb;62(2):249-258 [PMID: 30421138]
  80. Obstet Gynecol. 2018 Dec;132(6):e228-e248 [PMID: 30461693]
  81. Diabetes Care. 2019 Jan;42(Suppl 1):S165-S172 [PMID: 30559240]
  82. Obstet Gynecol. 2019 Jan;133(1):e26-e50 [PMID: 30575676]
  83. J Am Coll Cardiol. 2019 Jan 8;73(1):44-53 [PMID: 30621950]
  84. BMC Nephrol. 2019 Jan 23;20(1):24 [PMID: 30674290]
  85. J Clin Endocrinol Metab. 2019 Jul 1;104(7):2569-2579 [PMID: 30794722]

Grants

  1. T32 DK007012/NIDDK NIH HHS
  2. T32 HL007609/NHLBI NIH HHS

MeSH Term

Blood Glucose Self-Monitoring
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Female
Humans
Hypoglycemia
Hypoglycemic Agents
Insulin
Long-Acting Reversible Contraception
Pregnancy
Pregnancy in Diabetics

Chemicals

Hypoglycemic Agents
Insulin

Word Cloud

Created with Highcharts 10.0.0diabetespregnancytyperiskneonataloutcomespreexisting1maternalcanwomen2adversepreeclampsiadeliverycongenitaldefectsWomenincreasedsimilarriskscareplanningminimizegoalsless6comorbidnephropathyglycemiccontroltherapyPreexistingImportance:presenceincreasescesareanpretermmacrosomiaApproximately09%4millionbirthsUnitedStatesannuallycomplicatedObservations:presentformsrequireintensityPreconceptionimportantavoidunintendedpregnanciesHemoglobinA1c5%conception0%alsocriticalscreenmanageillnessesretinopathyMedicationsknownunsafeangiotensin-convertingenzymeinhibitorsstatinsdiscontinuedobesityscreenedobstructivesleepapneaoftenundiagnosedresultpoorBloodpressuremustconsideredcarefullylowertreatmentthresholdsmayrequiredcontinuousglucosemonitoringimproveInsulinfirst-lineinjectionsinsulinpumpeffectiveapproachesRatesseverehypoglycemiathereforeglucagonavailablepatientclosecontactstraineduseLow-doseaspirinrecommendedsoon12weeks'gestationimportancediscussinglong-actingreversiblecontraceptionallowappropriatepreconceptionoverstatedConclusionsRelevance:complexassociatedsignificantOptimizationmedicationregimenscarefulattentionconditionshelpmitigateensurequalityManagementDiabetesPregnancy:Review

Similar Articles

Cited By